FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide–platinum combination in patients with neuroendocrine carcinomas grade 3

Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy

(2011) Staffan Welin et al.   CANCER

Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma

(2011) Hedia Brixi-Benmansour et al.   DIGESTIVE AND LIVER DISEASE

Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas

(2010) O. Hentic et al.   ENDOCRINE-RELATED CANCER

The NANETS Consensus Guidelines for the Diagnosis and Management of Poorly Differentiated (High-Grade) Extrapulmonary Neuroendocrine Carcinomas

(2010) Jonathan R. Strosberg et al.   PANCREAS

Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours

(2008) R. Bettini et al.   ANNALS OF ONCOLOGY

One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY